Dana Blankenhorn

Dana Blankenhorn

Expertise: Technology, Biotech, Renewable energy

Education: M.S,J. Northwestern (Medill School) 1978; B.A. Rice University, History and Political Science 1977

Awards & Accomplishments: Tech reporter since 1982, Freelance since 1983, on Internet since 1985. Created first online coverage of Internet with a magazine, Interactive Age, 1994 Co-wrote BBS Systems for Business in 1991, Wrote Guide to Field Computing in 1992 Wrote technology history now called "Living with Moore's Law" in 2001, 2010, 2021 Author of over a dozen books, both fiction and non-fiction

About Dana:
Dana Blankenhorn has been a financial journalist since 1978, a technology journalist since 1982, and an Internet journalist since 1985. He writes a Substack newsletter, Facing the Future, which covers technology, markets, and politics.

He has written a half-dozen technology books, several novels available at the Amazon Kindle store, and covered beats ranging from education to e-commerce, and from open source to renewable energy. He lives in Atlanta.

Recent Articles

The Honeymoon Is Over for Lucid as the SEC Investigates Its Merger

LCID stock peaked when it won Motor Trend's Car of the Year award, and now the SEC is asking questions about its past.

What Will Parag Agrawal Do for Twitter Shareholders

Twitter has rolled out several services aimed at generating revenue beyond advertising, but new CEO Parag Agrawal still faces the task of making the site feel safe to celebrities again.

Even Good Penny Stocks Like Senseonics Aren’t Always Profitable

Its latest implanted sensor lasts six months, but SENS stock faces competition from Dexcom, Abbott Labs and potentially one big name in tech.

Investors Need To View Amazon as More Than Just One Business

Amazon Web Services rules the cloud. Prime Video could rule TV. Amazon's store has nothing but problems. Changing that could stoke AMZN stock.

Regeneron: Surfing on Covid, With More Under the Surface

Regeneron has made billions from its Covid-19 drug, and it has new drugs like Dupixent that could make many billions more.